| Targeting BET bromodomain proteins in solid tumors V Sahai, AJ Redig, KA Collier, FD Eckerdt, HG Munshi Oncotarget 7 (33), 53997, 2016 | 104 | 2016 |
| Acquired resistance to poly (ADP-ribose) polymerase inhibitor olaparib in BRCA2-associated prostate cancer resulting from biallelic BRCA2 reversion mutations restores both … BA Carneiro, KA Collier, RJ Nagy, S Pamarthy, V Sagar, S Fairclough, ... JCO precision oncology 2, 2018 | 67 | 2018 |
| A comprehensive review of heregulins, HER3, and HER4 as potential therapeutic targets in cancer JM Mota, KA Collier, RLB Costa, T Taxter, A Kalyan, CA Leite, YK Chae, ... Oncotarget 8 (51), 89284, 2017 | 67 | 2017 |
| Clinical activity and safety of cabozantinib for brain metastases in patients with renal cell carcinoma L Hirsch, NM Chanza, S Farah, W Xie, R Flippot, DA Braun, N Rathi, ... JAMA oncology 7 (12), 1815-1823, 2021 | 49 | 2021 |
| A framework for clinical cancer subtyping from nucleosome profiling of cell-free DNA AL Doebley, M Ko, H Liao, AE Cruikshank, K Santos, C Kikawa, JB Hiatt, ... Nature Communications 13 (1), 7475, 2022 | 39 | 2022 |
| Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Secondary Analysis of the BrighTNess Phase 3 … DG Stover, S Asad, PJ Ansell, M Watson, S Loibl, CE Geyer Jr, J Bae, ... JAMA oncology 7 (4), 603-608, 2021 | 39 | 2021 |
| Interplay between interferon regulatory factor 1 and BRD4 in the regulation of PD-L1 in pancreatic stellate cells K Ebine, K Kumar, TN Pham, MA Shields, KA Collier, M Shang, ... Scientific reports 8 (1), 13225, 2018 | 37 | 2018 |
| Real-time observation of impurity diffusion in silicon nanowires VC Holmberg, KA Collier, BA Korgel Nano letters 11 (9), 3803-3808, 2011 | 30 | 2011 |
| A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies KA Collier, H Valencia, H Newton, EM Hade, DW Sborov, R Cavaliere, ... Cancer chemotherapy and pharmacology 87, 599-611, 2021 | 19 | 2021 |
| Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness O Metzger-Filho, K Collier, S Asad, PJ Ansell, M Watson, J Bae, ... NPJ Breast Cancer 7 (1), 142, 2021 | 16 | 2021 |
| Sex-biased adaptive immune regulation in cancer development and therapy JM Schafer, T Xiao, H Kwon, K Collier, Y Chang, H Abdel-Hafiz, C Bolyard, ... Iscience 25 (8), 2022 | 15 | 2022 |
| Early phase clinical studies of AR‐42, a histone deacetylase inhibitor, for neurofibromatosis type 2‐associated vestibular schwannomas and meningiomas DB Welling, KA Collier, SS Burns, JL Oblinger, E Shu, BA Miles‐Markley, ... Laryngoscope investigative otolaryngology 6 (5), 1008-1019, 2021 | 15 | 2021 |
| Metastatic breast cancer patient perceptions of somatic tumor genomic testing EJ Adams, S Asad, R Reinbolt, KA Collier, M Abdel-Rasoul, S Gillespie, ... BMC cancer 20, 1-11, 2020 | 14 | 2020 |
| Prospective decision analysis study of clinical genomic testing in metastatic breast cancer: impact on outcomes and patient perceptions DG Stover, RE Reinbolt, EJ Adams, S Asad, K Tolliver, M Abdel-Rasoul, ... JCO Precision Oncology 3, 1-11, 2019 | 13 | 2019 |
| A multicenter study assessing survival in patients with metastatic renal cell carcinoma receiving immune checkpoint inhibitor therapy with and without cytoreductive nephrectomy EE Gross, M Li, M Yin, D Orcutt, D Hussey, E Trott, SK Holt, ER Dwyer, ... Urologic Oncology: Seminars and Original Investigations 41 (1), 51. e25-51. e31, 2023 | 11 | 2023 |
| Modeling clonal structure over narrow time frames via circulating tumor DNA in metastatic breast cancer ZT Weber, KA Collier, D Tallman, J Forman, S Shukla, S Asad, J Rhoades, ... Genome medicine 13 (1), 89, 2021 | 11 | 2021 |
| Combining immune checkpoint inhibition plus tyrosine kinase inhibition as first and subsequent treatments for metastatic renal cell carcinoma Y Yang, SP Psutka, AB Parikh, M Li, K Collier, A Miah, SV Mori, M Hinkley, ... Cancer Medicine 11 (16), 3106-3114, 2022 | 10 | 2022 |
| Activity and safety of cabozantinib (cabo) in brain metastases (BM) from metastatic renal cell carcinoma (mRCC): An international multicenter study. L Hirsch, N Martinez Chanza, S Farah, R Flippot, N Rathi, K Collier, ... Journal of clinical oncology 39 (6_suppl), 310-310, 2021 | 9 | 2021 |
| Multidimensional molecular profiling of metastatic triple-negative breast cancer and immune checkpoint inhibitor benefit R Barroso-Sousa, J Forman, K Collier, ZT Weber, TR Jammihal, KZ Kao, ... JCO Precision Oncology 6, e2100413, 2022 | 8 | 2022 |
| Salvage nivolumab and ipilimumab after prior anti‐PD‐1/PD‐L1 therapy in metastatic renal cell carcinoma: A meta‐analysis Y Yang, SV Mori, M Li, M Hinkley, AB Parikh, KA Collier, A Miah, M Yin Cancer Medicine 11 (7), 1669-1677, 2022 | 5 | 2022 |
